A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours

European Journal of Cancer

Volumn 45, Issue 13, 2009, Pages 2352-2359

  Baruchel, Sylvain ^a   Sharp, Julia R ^a   Bartels, Ute ^a   Hukin, Juliette ^b   Odame, Isaac ^c   Portwine, Carol ^c   Strother, Doug ^d   Fryer, Chris ^b   Halton, Jackie ^e   Egorin, Merrill J ^f   Reis, Rui Manuel ^g   Martinho, Olga ^g   Stempak, Diana ^a   Hawkins, Cynthia ^a   Gammon, Janet ^a   Bouffet, Eric ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d ALBERTA CHILDREN'S HOSPITAL   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MINHO   (Portugal)

Author keywords

Brain neoplasms; C kit; Central nervous system neoplasms; Drug toxicity; Imatinib; Paediatrics; Pharmacokinetics; Phase II; Platelet derived growth factor alpha receptor

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; ANOREXIA; ARTICLE; ASTROCYTOMA; ATAXIA; BLURRED VISION; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID ANALYSIS; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; EPENDYMOMA; FATIGUE; FEMALE; GENE AMPLIFICATION; GLIOMA; HEMATURIA; HUMAN; HYPOALBUMINEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEDULLOBLASTOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; NEUROEPITHELIOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR BLEEDING; TUMOR RECURRENCE; WEIGHT REDUCTION; WHEEZING;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CANADA; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 68749098341     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.008     Document Type: Article

References (32)

1. Gurney JG, Smith MA, Bunin GR. CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995, NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999. p. 51-63.
2. Radcliffe J., Bunin G.R., Sutton L.N., Goldwein J.W., and Phillips P.C. Cognitive deficits in long-term survivors of childhood medulloblastoma and other noncortical tumors: age-dependent effects of whole brain radiation. Int J Dev Neurosci 12 4 (1994) 327-334
3. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derive d growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
4. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase by STI571, selective tyrosine kinase inhibitor. Blood 965 (2000) 925-932
5. Williams D.E., Eisenman J., Baird A., et al. Identification of a ligand for the c-kit proto-oncogene. Cell 63 1 (1990) 167-174
6. Geissler E.N., Ryan M.A., and Housman D.E. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55 (1988) 185-192
7. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
8. Isozaki K., Terris B., Belghiti J., Schiffmann S., Hirota S., and Vanderwinden J.M. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 157 (2000) 1581-1585
9. Williams L.T. Signal transduction by the platelet-derived growth factor receptor. Science 243 4898 (1989) 1564-1570 [Review]
10. Beppu K., Jaboine J., Merchant M.S., Mackall C.L., and Thiele C.J. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96 1 (2004) 46-55
11. van Oosterom A.T., Judson I.R., Verweij J., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 5 (2002) S83-S87
12. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
13. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 6 (2002) 1928-1937
14. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 104 9 (2004) 2655-2660
15. Kolb E.A., Pan Q., Ladanyi M., and Steinherz P.G. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer 98 12 (2003) 2643-2650
16. Chilton-Macneill S., Ho M., Hawkins C., Gassas A., Zielenska M., and Baruchel S. C-kit expression and mutational analysis in medulloblastoma. Pediatr Dev Pathol 7 5 (2004) 493-498
17. Smithey B.E., Pappo A.S., and Hill D.A. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 26 4 (2002) 486-492
18. Sakuma Y., Sakurai S., Oguni S., Satoh M., Hironaka M., and Saito K. c-Kit gene mutations in intracranial germinomas. Cancer Sci 95 9 (2004) 716-720
19. Liang M.L., Ma J., Ho M., et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol 87 3 (2008) 247-253
20. Di Sapio A., Morra I., Pradotto L., Guido M., Schiffer D., and Mauro A. Molecular genetic changes in a series of neuroepithelial tumors of childhood. J Neurooncol 59 2 (2002) 117-122
21. Parise R.A., Ramanathan R.K., Hayes M.J., and Egorin M.J. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 791 1-2 (2003) 39-44
22. Gomes A.L., Reis-Filho J.S., Lopes J.M., et al. Molecular alterations of KIT oncogene in gliomas. Cell Oncol 29 (2007) 399-408
23. Pollack I.F., Jakacki R.I., Blaney S.M., et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a pediatric brain tumor consortium report. Neuro Oncol 9 2 (2007) 145-160
24. Raymond E., Brandes A.A., Dittrich C., et al. European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26 28 (2008) 4659-4665
25. Wen P.Y., Yung W.K., Lamborn K.R., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99-08. Clin Cancer Res 12 16 (2006) 4899-4907
26. Takayama N., Sato N., O'Brien S.G., Ikeda Y., and Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119 1 (2002) 106-108
27. Bornhauser M., Jenke A., Freiberg-Richter J., et al. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 83 6 (2004) 401-402
28. Dai H., Marbach P., Lemaire M., Hayes M., and Elmquist W.F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304 3 (2003) 1085-1092
29. Porkka K., Koskenvesa P., Lundán T., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112 4 (2008) 1005-1012
30. Debiec-Rychter M., Dumez H., Judson I., et al. EORTC Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRΑ mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40 5 (2004) 689-695
31. Debiec-Rychter M., Sciotb R., Le Cesned A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 (2006) 1093-1103
32. Reardon D.A., Desjardins A., Vredenburgh J.J., et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol 10 3 (2008) 330-340